Adipotide
Also known as: FTPP, Prohibitin-Targeting Peptide 1, Fat-Targeted Proapoptotic Peptide
A peptide that targets and destroys fat tissue blood vessels, causing rapid fat loss.
Overview
Adipotide (FTPP) is a peptidomimetic that targets the blood supply of white adipose tissue. It contains a targeting sequence that binds to prohibitin on fat tissue blood vessels and a proapoptotic sequence that kills those cells, causing fat tissue to shrink due to lack of blood supply.
Mechanism of Action
Contains two domains: a targeting domain (CKGGRAKDC) that binds prohibitin on adipose vasculature, and a proapoptotic domain (D(KLAKLAK)2) that induces mitochondrial membrane disruption and apoptosis in targeted cells.
Pharmacokinetics
Short half-life. Subcutaneous or IV administration. Rapid tissue distribution.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Research Only
0.5-1 mg/kg
Daily
4 weeks
EXTREMELY HIGH RISK - renal monitoring essential
Research Areas
Key Research Findings
- 139% fat loss in obese rhesus monkeys over 4 weeks
- 2Targeted destruction of fat tissue vasculature
- 3Improved insulin sensitivity in animal models
- 4Significant renal toxicity observed
Side Effects & Contraindications
Reported Side Effects
- Renal toxicity (significant)
- Dehydration
- Electrolyte imbalances
- Potential kidney failure
Contraindications
- Kidney disease
- Renal impairment
- Any kidney risk factors
- Human use outside research
Safety Considerations
HIGH RISK - causes significant kidney damage. Renal toxicity is dose-limiting. NOT suitable for human use outside controlled research. Requires extensive monitoring.
Storage Requirements
Store at -20°C
Scientific References
- 1